Navigation Links
Prometheus Laboratories and UCLA Sign Agreement to Validate Biological Markers of Mucosal Healing in IBD

SAN DIEGO, Dec. 9, 2010 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, and The Regents of the University of California, Los Angeles campus, today announced the execution of an exclusive research agreement that will focus on the identification of biological markers of mucosal healing in patients with Inflammatory Bowel Disease (IBD). The research will be led by Dr. Jonathan Braun, Chair of the Department of Pathology and Laboratory Medicine and a professor of molecular and medical pharmacology, UCLA David Geffen School of Medicine.

Using a cross sectional study design, Dr. Braun's laboratory will determine the correlation of genotoxicity markers to mucosal healing and disease activity in IBD patients. Prometheus will evaluate in its laboratory, additional markers of inflammation and other markers traditionally associated with the diagnosis and prognosis of IBD.

"We have come to realize that symptom response is not a true indication that a drug has been effective in stopping the progression of IBD. We need to look at mucosal healing as a more accurate predictor of effective response," said Dr. Jonathan Braun. "There is a clinical need for a non-invasive biomarker of mucosal healing as currently this has been seen using a colonoscopy."

"Adding this research project to our R&D portfolio is the latest in a series of investments Prometheus has made to answer the clinical questions related to optimization of the use of biologic therapies commonly used in IBD treatment," said Joseph M. Limber, President & Chief Executive Officer of Prometheus. "Our goal is to be able to answer the clinical questions of who will respond to these drugs up front, how one can manage patients most effectively while on these drugs and to have a non-invasive measurement of treatment efficacy."

Under the terms of the exclusive agreement, Prometheus will fund the research activities in Dr. Braun's laboratory in exchange for rights to any intellectual property generated as a result of the project. Prometheus holds a license to technology Dr. Braun co-invented and Dr. Braun is a co-founder of Prometheus. 

About Prometheus

Prometheus Laboratories Inc. is committed to improving lives through the development and commercialization of novel pharmaceutical and diagnostic products that enable physicians to provide greater individualized patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and is applying these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary diagnostic testing services. By integrating therapeutics and diagnostics, Prometheus believes it can provide physicians with more targeted solutions to optimize care for their patients. Prometheus' corporate offices are located in San Diego, California.

SOURCE Prometheus Laboratories Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Prometheus Research Launches Solutions Group to Springboard HTSQL-based Solutions for Customers
2. Prometheus and Tarrot Laboratories Collaborate to Identify Markers Associated With Response to Anti-TNF Therapies in Crohns Disease
3. Prometheus Research Informatics Technology Enables Multiple Presentations at IMFAR
4. Prometheus Research Awarded National Science Foundation Grant for Easy to Use, Web-Enabled Database Software
5. DNA Genotek Sample Collection Kit Selected by Prometheus for MyCeliacID™ Genetic Test
6. Prometheus Research Signs 3-Year Contract With Simons Foundation to Expand HTSQL Informatics System for Autism Research
7. Prometheus Receives New York State Approval for PROMETHEUS(R) IBS Diagnostic, First Blood Test for Irritable Bowel Syndrome
8. Prometheus Strengthens Intellectual Property Portfolio with Newly Issued Patents for Thiopurine Metabolite Testing
9. Terso Solutions RFID Jump Start Takes the Risk Out of Implementing RFID for Hospitals and Research Laboratories Looking to Streamline Operations and Improve Regulatory Compliance
10. MO BIO Laboratories, Inc. DNA Isolation Products Used to Analyze Microbes Present in Deepwater Horizon Oil Plume
11. Forensic Laboratories Develops First Oral Fluid Test for Ethyl Sulfate Detection
Post Your Comments:
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
(Date:6/23/2016)... adds 2016 global ... pharmaceuticals section with historic and forecast data along ... Complete report on the Cell Culture ... companies and supported with 261 tables and figures ... The Global Cell Culture Media Industry ...
Breaking Biology Technology:
(Date:6/2/2016)... 2, 2016 Perimeter Surveillance & ... Systems, Physical Infrastructure, Support & Other Service  ... offers comprehensive analysis of the global Border ... generate revenues of $17.98 billion in 2016. ... a leader in software and hardware technologies for advanced ...
(Date:5/12/2016)... , May 12, 2016 ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... ) The integration ... security to access and transact across channels. Using ...
Breaking Biology News(10 mins):